Q3: 2025-11-06 Earnings Summary
EPS of $0.20 misses by $0.04
| Revenue of $1.50B (-0.40% Y/Y) misses by $2.98M
The Chemours Company (CC) Q3 2025 Earnings Call November 7, 2025 8:00 AM EST
Company Participants
Brandon Ontjes – Vice President of Investor Relations
Denise Dignam – President, CEO & Director
Shane Hostetter – Senior VP & CFO
Conference Call Participants
John McNulty – BMO Capital Markets Equity Research
Peter Osterland – Truist Securities, Inc., Research Division
John Ezekiel Roberts – Mizuho Securities USA LLC, Research Division
Arun Viswanathan – RBC Capital Markets, Research Division
Joshua Spector – UBS Investment Bank, Research Division
Patrick Fischer – Goldman Sachs Group, Inc., Research Division
Hassan Ahmed – Alembic Global Advisors
Laurence Alexander – Jefferies LLC, Research Division
Jeffrey Zekauskas – JPMorgan Chase & Co, Research Division
Vincent Andrews – Morgan Stanley, Research Division
Roger Spitz – BofA Securities, Research Division
Aaron Rosenthal – JPMorgan Chase & Co, Research Division
Presentation
Operator
Good morning. My name is Gigi, and I’ll be your conference operator today. I would like to welcome everyone to The Chemours Company Third Quarter 2025 Results Conference Call. [Operator Instructions]
I would like to remind everyone that this conference call is being recorded.
I would now like to hand the conference call over to Brandon Ontjes, Vice President, Head of Strategy and Investor Relations for Chemours. You may begin your conference.
Brandon Ontjes
Vice President of Investor Relations
Good morning, everybody. Welcome to the Chemours Company’s Third Quarter 2025 Earnings Conference Call. I’m joined today by Denise Dignam, Chemours’ President and Chief Executive Officer; and our Senior Vice President and Chief Financial Officer, Shane Hostetter.
Before we start, I would like to remind you that comments made on this call as well as in the supplemental information provided on our website contain forward-looking statements that involve risks and uncertainties as described in Chemours’ SEC filings. These forward-looking statements are not guarantees of future performance and are based on certain assumptions and expectations of future
Read the full article here
